Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings.

The Company is developing its lead antibiotic, oritavancin, in an intravenous (IV) formulation for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection. Targanta submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in February 2008 seeking to commercialize oritavancin for the treatment of cSSSI; the FDA accepted the NDA submission for standard review, establishing an action date of December 8, 2008. Additionally, Targanta's Marketing Authorization Application (MAA) for oritavancin was accepted for review by the European Medicines Agency (EMEA) in June 2008. Targanta is also developing a number of antibacterial agents currently in pre-clinical development, including an oral version of oritavancin targeting Clostridium difficile-related conditions.

Targanta's strategy is to develop oritavancin into a leading therapy worldwide for the treatment of serious gram-positive infections, initially for the treatment of cSSSI and subsequently for other indications. Specifically, Targanta intends to:

• Obtain regulatory approval for IV oritavancin for the treatment of complicated skin infection in both the U.S. and Europe;
• Build a hospital-directed sales force to commercialize IV oritavancin in the U.S.;
• Evaluate the potential for a blended commercialization strategy for IV oritavancin in the European Union;
• Out-license oritavancin to third parties for development and commercialization in key Asian countries; and
• Pursue the development of other innovative antibiotics for the hospital market, either through in-licensing or internal development.

The Company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Québec, Canada.

The Company's common stock trades on the Nasdaq under the symbol: TARG

Download Corporate Fact Sheet